ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 11/14/23

2023-11-14 10:35:54 ET Summary Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in combination with chemotherapy, and as a monotherapy....

Investor call to be held on Friday, November 10 th , at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15 th , 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GL...

2023-11-08 11:58:55 ET More on Zentalis Pharmaceuticals Zentalis: A Buy As Small Molecule Trials Continue To Advance Zentalis hits 52-week low as Leerink downgrades on data for lead asset Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals Histori...

2023-11-07 14:36:10 ET Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) lost ~21% to reach a new 52-week low on Tuesday after the cancer drug developer updated Phase 1 data for its lead candidate, azenosertib, leading to a downgrade from Leering Partners. With its Q3 2023 financial...

Zentalis Pharmaceuticals Inc. (ZNTL) is expected to report $-1.01 for Q3 2023

2023-11-06 12:51:18 ET Gainers: MSP Recovery ( LIFW ) +458% . Bluegreen Vacations Holding Corporation ( BVH ) +106% . Tenon Medical ( TNON ) +72% . Cano Health ( CANO ) +43% . Cheetah Net Supply Chain Service ( CTNT ) +36% . ...

2023-11-06 07:26:48 ET More on Zentalis Pharmaceuticals Zentalis: A Buy As Small Molecule Trials Continue To Advance Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals Historical earnings data for Zentalis Pharmaceuticals Financial information fo...

NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today a...

2023-08-24 09:42:43 ET Summary Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show a solid cash position and efficient allocation of resources. Zentalis has a diverse pipeline of ...

2023-08-09 12:12:37 ET Zentalis Pharmaceuticals press release ( NASDAQ: ZNTL ): Q2 GAAP EPS of -$1.85. Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million. For further details s...